Although we could not fully disentangle the relationship between ASH2L, H3K4me3, and resistance to DNA damaging agents, the results presented here clearly indicate that low levels of ASH2L in cancer cells could be used to predict genotoxin resistance but not resistance to ATR inhibitors, which are in clinical trials at the moment75. The gene discussed is ASH2L; the disease is cancer.